Status:
COMPLETED
A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia
Lead Sponsor:
GlaxoSmithKline
Conditions:
Sleep Initiation and Maintenance Disorders
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects participate in a clinical screening visit and a two-night PSG recording session in the sleep laboratory. Eligi...
Eligibility Criteria
Inclusion
- Healthy male and female subjects with primary insomnia with normal EG may be eligible for inclusion.
Exclusion
- clinically significant physical or psychiatric illness or abnormal sleep patterns.
Key Trial Info
Start Date :
July 30 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2005
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00650871
Start Date
July 30 2004
End Date
August 30 2005
Last Update
August 8 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
San Diego, California, United States, 92123
2
GSK Investigational Site
Atlanta, Georgia, United States, 30342
3
GSK Investigational Site
New York, New York, United States, 10025
4
GSK Investigational Site
Durham, North Carolina, United States, 27705